Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea
Journal of Clinical Neurology · 2025 · 21 (2) · 131
DOI: 10.3988/jcn.2024.0485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Neurology, 2025. Verfasst von Su-Hyun Kim und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND AND PURPOSE: Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. METHODS: We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. RESULTS: The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15-87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse. Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. CONCLUSIONS: This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Neurology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
- Department of Neurology, Chungnam National University of Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
ORCID-Profile: Su-Hyun Kim, Ju-Hong Min, Sung-Min Kim, Eun-Jae Lee, Young-Min Lim, Ha Young Shin, Young Nam Kwon, Eunhee Sohn, Sooyoung Kim, Min Su Park, Tai-Seung Nam, Byeol-A Yoon, Jong Kuk Kim, Kyong Jin Shin, Yoo Hwan Kim, Jin Myoung Seok, Jeong Bin Bong, Sohyeon Kim, Hung Youl Seok, Sun-Young Oh, Ohyun Kwon, Sunyoung Kim, Sukyoon Lee, Nam-Hee Kim, Eun Bin Cho, Sa-Yoon Kang, Seong-Il Oh, Jong Seok Bae, Suk-Won Ahn, Ki Hoon Kim, You-Ri Kang, Woohee Ju, Seung Ho Choo, Yeon Hak Chung, Jae-Won Hyun, Ho Jin Kim
Zitieren
APA
Kim, S. H., Min, J. H., Kim, S. M., Lee, E. J., Lim, Y. M., Shin, H. Y., Kwon, Y. N., Sohn, E., Kim, S., Park, M. S., Nam, T. S., Yoon, B. A., Kim, J. K., Shin, K. J., Kim, Y. H., Seok, J. M., Bong, J. B., Kim, S., Seok, H. Y., …, & Kim, H. J. (2025). Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea. Journal of Clinical Neurology, 21(2), 131. https://doi.org/10.3988/jcn.2024.0485
Vancouver
Kim SH, Min JH, Kim SM, Lee EJ, Lim YM, Shin HY, et al. Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea. Journal of Clinical Neurology. 2025;21(2):131. doi:10.3988/jcn.2024.0485
BibTeX
@article{Kim2025,
author = {Kim, Su-Hyun and Min, Ju-Hong and Kim, Sung-Min and Lee, Eun-Jae and Lim, Young-Min and Shin, Ha Young and Kwon, Young Nam and Sohn, Eunhee and Kim, Sooyoung and Park, Min Su and Nam, Tai-Seung and Yoon, Byeol-A and Kim, Jong Kuk and Shin, Kyong Jin and Kim, Yoo Hwan and Seok, Jin Myoung and Bong, Jeong Bin and Kim, Sohyeon and Seok, Hung Youl and Oh, Sun-Young and Kwon, Ohyun and Kim, Sunyoung and Lee, Sukyoon and Kim, Nam-Hee and Cho, Eun Bin and Kang, Sa-Yoon and Oh, Seong-Il and Bae, Jong Seok and Ahn, Suk-Won and Kim, Ki Hoon and Kang, You-Ri and Ju, Woohee and Choo, Seung Ho and Chung, Yeon Hak and Hyun, Jae-Won and Kim, Ho Jin},
title = {Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea},
journal = {Journal of Clinical Neurology},
year = {2025},
volume = {21},
number = {2},
pages = {131},
doi = {10.3988/jcn.2024.0485}
}
EUVIMED